Indaptus Therapeutics (NASDAQ:INDP) Announces Earnings Results

Posted by Geri Gentry on May 15th, 2026

Indaptus Therapeutics (NASDAQ:INDP – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($1.87) by $1.64, Zacks reports.

Indaptus Therapeutics Price Performance

INDP stock traded down $0.16 on Friday, reaching $1.59. 82,975 shares of the company traded hands, compared to its average volume of 64,396. Indaptus Therapeutics has a one year low of $1.51 and a one year high of $19.91. The company has a market cap of $3.56 million, a P/E ratio of -0.07 and a beta of 1.37. The firm has a fifty day simple moving average of $2.16 and a 200-day simple moving average of $2.33.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Get Our Latest Report on Indaptus Therapeutics

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Indaptus Therapeutics, Inc. (NASDAQ:INDP – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics as of its most recent SEC filing. 7.06% of the stock is owned by hedge funds and other institutional investors.

Indaptus Therapeutics Company Profile

(Get Free Report)

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.